Skip to main content

Table 3 Subgroup analysis on the associations between PDCD4 expression and OS, DSS, and DFS/RFS of patients with solid tumors

From: The clinical association of programmed cell death protein 4 (PDCD4) with solid tumors and its prognostic significance: a meta-analysis

Parameter OS DSS DFS/RFS
Reference(s) HR 95% CI I 2 (%) P References HR 95% CI I 2 (%) P References HR 95% CI I 2 (%) P
Total [7, 15, 17, 18, 24, 28–31, 33] 2.24 1.93–2.60 42.1 0.025 [24, 28, 32, 34] 3.59 1.23–10.50 80.5 0.002 [29–31, 33, 35] 2.01 1.58–2.56 28.6 0.181
 Univariate [15, 18, 29–31] 2.05 1.69–2.49 59.4 0.016 None NA NA NA NA [29–31] 2.05 1.16–3.63 51.1 0.105
 Multivariate [7, 17, 18, 24, 28–31, 33] 2.52 2.01–3.16 19.6 0.251 [24, 28, 32, 34] 3.59 1.23–10.50 80.5 0.002 [29–31, 33, 35] 2.37 1.69–3.33 0 0.456
Brain tumor None NA NA NA NA [32] 15.87 3.62–71.43 NA NA None NA NA NA NA
 Univariate None NA NA NA NA None NA NA NA NA None NA NA NA NA
 Multivariate None NA NA NA NA [32] 15.87 3.62–71.43 NA NA None NA NA NA NA
Head and neck cancer [18, 24, 29] 3.44 2.38–4.98 41.9 0.142 [24] 5.05 1.12–62.50 NA NA [29] 2.10 1.30–3.39 47.4 0.149
 Univariate [18, 29] 10.70 0.58–197.75 74.5 0.047 None NA NA NA NA [29] 7.46 1.04–52.63 NA NA
 Multivariate [18, 24, 29] 3.24 1.93–5.45 29.7 0.241 [24] 5.05 1.12–62.50 NA NA [29] 1.94 1.19–3.18 52.4 0.147
Breast cancer [30] 1.86 1.36–2.54 28.1 0.238 None NA NA NA NA [30] 1.23 0.79–1.92 NA NA
 Univariate [30] 1.61 1.09–2.38 NA NA None NA NA NA NA [30] 1.23 0.79–1.92 NA NA
 Multivariate [30] 2.38 1.43–4.00 NA NA None NA NA NA NA None NA NA NA NA
Digestive system cancer [7, 15, 28, 31] 2.12 1.75–2.56 36.2 0.101 [28] 1.31 1.00–1.72 NA NA [31, 33] 2.57 1.74–3.78 0 0.877
 Univariate [15, 31] 2.14 1.49–3.06 43.8 0.130 None NA NA NA NA [31] 2.50 1.45–4.30 0 0.857
 Multivariate [7, 15, 28, 31] 2.33 1.73–3.13 36.6 0.149 [28] 1.31 1.00–1.72 NA NA [31, 33] 2.64 1.52–4.58 0 0.562
Gynecologic tumor None NA NA NA NA [34] 3.36 1.43–7.81 NA NA [35] 3.42 1.41–8.33 NA NA
 Univariate None NA NA NA NA None NA NA NA NA None NA NA NA NA
 Multivariate None NA NA NA NA [34] 3.36 1.43–7.81 NA NA [35] 3.42 1.41–8.33 NA NA
Urinary system cancer [17] 3.16 1.06–9.41 NA NA None NA NA NA NA None NA NA NA NA
 Univariate None NA NA NA NA None NA NA NA NA None NA NA NA NA
 Multivariate [17] 3.16 1.06–9.41 NA NA None NA NA NA NA None NA NA NA NA
Asian [7, 15, 17, 18, 24, 28, 31] 2.46 2.06–2.95 23.5 0.193 [24, 32, 34] 5.67 2.13–5.12 36.6 0.206 [31, 33, 35] 2.69 1.88–3.83 0 0.908
 Univariate [15, 18, 31] 2.34 1.66-3.30 50.6 0.072 None NA NA NA NA [31] 2.50 1.45–4.30 0 0.857
 Multivariate [7, 17, 24, 28, 31] 3.05 2.26–4.11 0.0 0.750 [24, 32, 34] 5.67 2.13–5.12 36.6 0.206 [31, 33, 35] 2.84 1.78–4.53 0 0.708
European [28] 1.56 1.05–2.67 NA NA [28] 1.31 1.00–1.72 NA NA None NA NA NA NA
 Univariate None NA NA NA NA None NA NA NA NA None NA NA NA NA
 Multivariate [28] 1.56 1.05–2.67 NA NA [28] 1.31 1.00–1.72 NA NA None NA NA NA NA
North American [29, 30] 1.99 1.46–2.71 71.7 0.014 None NA NA NA NA [29, 30] 1.58 1.14–2.18 52.9 0.095
 Univariate [29, 30] 7.95 0.20–311.36 83.6 0.014 None NA NA NA NA [29, 30] 2.33 0.43–12.57 67.5 0.080
 Multivariate [29] 2.56 1.54–4.25 66.9 0.082 None NA NA NA NA [29] 1.94 1.19–3.18 52.4 0.147
Publication bias                
 Begg’s test      0.940      0.308      0.902
 Egger’s test      0.744      0.215      0.550
  1. OS overall survival, DSS disease-specific survival, DFS disease-free survival, RFS relapse-free survival, HR hazard ratio, CI confidence interval, NA not available
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us